BOSTON and SINGAPORE--(BUSINESS WIRE)--Jan. 19, 2006--CombinatoRx, Incorporated, -- (NASDAQ: CRXX) and Bio*One Capital of Singapore, today announced the establishment of CombinatoRx Singapore Pte Ltd. CombinatoRx Singapore and Bio*One also announced that Sir David Lane has joined the CombinatoRx Singapore Board of Directors.
CombinatoRx Singapore, will apply CombinatoRx's combination high throughput screening (cHTS) technology to discover and potentially develop novel product candidates to treat infectious diseases, with an initial focus on Hepatitis C and Hepatitis B.
